JUPITER
2008
Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
In 17,802 adults with LDL < 130 mg/dL and hsCRP ≥ 2 mg/L, rosuvastatin reduced major vascular events versus placebo.
Result
Efficacy: MI, stroke, hosp UA, revasc or CV deathHR 0.56
Below 1 favours rosuvastatin, above 1 favours placebo.
Event rates Rosuvastatin 0.77 vs placebo 1.36 per 100 patient-years
- Subtopic
- Statins
- Design
- Double-blind RCT, stopped early at median 1.9 yr
- Relevance
- Important: one of several pillars.
- Source
- Ridker PM, et al. N Engl J Med. 2008;359(21):2195-2207.doi 10.1056/NEJMoa0807646
Discussion & critique
Extended statin benefit to apparently 'normal-LDL' primary prevention with inflammatory risk. Early termination + commercial sponsorship drew criticism; reanalyses confirmed signal.